|Other Names||Transcription factor AP-1, Activator protein 1, AP1, Proto-oncogene c-Jun, V-jun avian sarcoma virus 17 oncogene homolog, p39, JUN|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2507b is HPRLQALKEEPQTVPE, containing a predicted sumoylation site from the C-terminal region of human AP-1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells (PubMed:24623306). Binds to the USP28 promoter in colorectal cancer (CRC) cells (PubMed:24623306).|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The gene for AP-1 is the putative transforming gene of avian sarcoma virus 17. AP-1 is highly similar to the viral protein, and interacts directly with specific target DNA sequences to regulate gene expression. The AP-1 gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies. AP-1 dimer activity is downregulated by SUMO-1, SUMO-2, and SUMO-3.
Bossis, et al., Mol Cell Biol. 2005 Aug;25(16):6964-79.Perez-Sala, D., et al., J. Biol. Chem. 278(51):51251-51260 (2003).Yang, H., et al., J. Biol. Chem. 278(51):50887-50896 (2003).Toborek, M., et al., J. Neurochem. 84(1):169-179 (2003).Wang, Y.N., et al., J. Biol. Chem. 278(46):45848-45857 (2003).
If you have any additional inquiries please email technical services at email@example.com.